185 related articles for article (PubMed ID: 35296780)
1. Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects.
Qian HJ; Wang Y; Zhang MQ; Xie YC; Wu QQ; Liang LY; Cao Y; Duan HQ; Tian GH; Ma J; Zhang ZB; Li N; Jia JY; Zhang J; Aisa HA; Shen JS; Yu C; Jiang HL; Zhang WH; Wang Z; Liu GY
Acta Pharmacol Sin; 2022 Dec; 43(12):3130-3138. PubMed ID: 35296780
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind Phase I study in healthy subjects.
Sun C; Liu H; Ouyang Z; Ding J; Zhang Q; Ma H; Xu D; Zhang Q; Zhou R; Yang M; Hu W
Expert Opin Investig Drugs; 2024 May; 33(5):533-542. PubMed ID: 38662639
[TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability, and pharmacokinetics of ibrexafungerp in healthy Chinese subjects: a randomized, double-blind, placebo-controlled phase 1 trial.
Liu X; Zhang R; Li R; Wu Q; Pan C; Yu X; Liu Y; Wang B; Yu S
Antimicrob Agents Chemother; 2023 Dec; 67(12):e0107523. PubMed ID: 37971243
[TBL] [Abstract][Full Text] [Related]
4. Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study.
Fan X; Dai X; Ling Y; Wu L; Tang L; Peng C; Huang C; Liu H; Lu H; Shen X; Zhang W; Wang F; Li G; Li M; Huang Y; Zhang H; Li M; Ren F; Li Y; Liu C; Zhou Z; Sun W; Yi Y; Zhou D; Gao H; Pan Q; Liu H; Zhao J; Ding Z; Ma Y; Li W; Wang Q; Wang X; Bai Y; Jiang X; Ma J; Xie B; Zhang K; Li L
Lancet Infect Dis; 2024 Feb; 24(2):129-139. PubMed ID: 38006892
[TBL] [Abstract][Full Text] [Related]
5. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
6. Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.
Fan Y; Zhang X; Zhang Q; Zheng L; Zhou R; Sun C; Wang X; Song K; He Z; Wang H; Zhang Q; Hu W
Clin Pharmacokinet; 2024 Mar; 63(3):293-302. PubMed ID: 38198010
[TBL] [Abstract][Full Text] [Related]
7. Safety, Tolerability, and Pharmacokinetics of the Novel Hepatitis B Virus Expression Inhibitor GST-HG131 in Healthy Chinese Subjects: a First-in-Human Single- and Multiple-Dose Escalation Trial.
Li X; Liu Y; Yao H; Wang M; Gao L; Lou J; Mao J; Wu W; Zhou Y; Tang Y; Yan W; Hu Y; Ding C; Chen S; Niu J; Ding Y
Antimicrob Agents Chemother; 2022 May; 66(5):e0009422. PubMed ID: 35404074
[TBL] [Abstract][Full Text] [Related]
8. Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Benfotiamine in Healthy Subjects.
Sheng L; Cao W; Lin P; Chen W; Xu H; Zhong C; Yuan F; Chen H; Li H; Liu C; Yang M; Li X
Drug Des Devel Ther; 2021; 15():1101-1110. PubMed ID: 33727798
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, Safety and Tolerability of Tylerdipine Hydrochloride, a Novel Dihydropyridine Dual L/T-type Calcium Channel Blocker, after Single and Multiple Oral Doses in Healthy Chinese Subjects.
Zhou S; Wang Y; Wang L; Xie L; Chen J; Liu Y; Zhang H; Zhao Y; Ou N; Shao F
Clin Drug Investig; 2019 Jan; 39(1):85-96. PubMed ID: 30368658
[TBL] [Abstract][Full Text] [Related]
10. Characterization of in-vivo human metabolites of the oral nucleoside anti-COVID-19 drug VV116 using UHPLC-Orbitrap-MS.
Zhou A; Wang Z; Diao X; Zhong D
J Pharm Biomed Anal; 2023 May; 228():115340. PubMed ID: 36924632
[TBL] [Abstract][Full Text] [Related]
11. A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TPN171H, a Novel Phosphodiesterase Type 5 Inhibitor, in Healthy Subjects.
Qian H; Chen Q; Liang L; Zou Y; Pu H; Xin L; Song R; Li T; Zhu H; Wang Y; Tian G; Shen J; Jiang H; Yu C; Wang Z; Jia J
Drug Des Devel Ther; 2021; 15():2947-2959. PubMed ID: 34262260
[TBL] [Abstract][Full Text] [Related]
12. Safety, tolerability, and pharmacokinetics of oral (S)-oxiracetam in Chinese healthy volunteers: A randomized, double-blind, controlled phase I study.
Zhang T; Tao Y; Pu J; Zhu M; Wan L; Tang C
Eur J Pharm Sci; 2024 Jan; 192():106621. PubMed ID: 37898393
[TBL] [Abstract][Full Text] [Related]
13. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652, a Reversible Fatty Acid Amide Hydrolase Inhibitor, in Healthy, Nonelderly, Japanese Men and Elderly, Japanese Men and Women: A Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Phase I Study.
Takizawa M; Hatta T; Iitsuka H; Katashima M; Sato Y; Kuroishi K; Nagashima H
Clin Ther; 2020 May; 42(5):906-923. PubMed ID: 32456804
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability and pharmacokinetics of trimebutine 3-thiocarbamoylbenzenesulfonate (GIC-1001) in a randomized phase I integrated design study: single and multiple ascending doses and effect of food in healthy volunteers.
Paquette JM; Rufiange M; Iovu Niculita M; Massicotte J; Lefebvre M; Colin P; Telmat A; Ranger M
Clin Ther; 2014 Nov; 36(11):1650-64. PubMed ID: 25224876
[TBL] [Abstract][Full Text] [Related]
16. Safety, Tolerability, and Pharmacokinetic Study of 101BHG-D01 Nasal Spray, a Novel Long-Acting and Selective Cholinergic M Receptor Antagonist, in Healthy Chinese Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation, First-In-Human Study.
Chu NN; Huang K; Que LL; Ding Y; Gu XH; Zhang L; Wang JK; Chen XP; Sun ZG; He Q
Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):509-521. PubMed ID: 35429285
[TBL] [Abstract][Full Text] [Related]
17. A phase I study to evaluate the safety, tolerability, and pharmacokinetics of a novel, potent GABA analog HSK16149 in healthy Chinese subjects.
Chen Q; Wu Q; Song R; Wang Y; Zhang M; Li F; Zeng W; Wang W; Jia J; Yu C; Liu Y
Front Pharmacol; 2023; 14():1296672. PubMed ID: 38146463
[No Abstract] [Full Text] [Related]
18. Safety, tolerability, and pharmacokinetics of a single ascending dose of baicalein chewable tablets in healthy subjects.
Li M; Shi A; Pang H; Xue W; Li Y; Cao G; Yan B; Dong F; Li K; Xiao W; He G; Du G; Hu X
J Ethnopharmacol; 2014 Oct; 156():210-5. PubMed ID: 25219601
[TBL] [Abstract][Full Text] [Related]
19. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652 in First-in-Human and Ascending Multiple Oral Dose Studies in Healthy Subjects.
Takizawa M; Cerneus D; Michon I; Rijnders S; van der Heide D; Meijer J; Stoelzel M; Sato Y
Adv Ther; 2020 Sep; 37(9):3878-3900. PubMed ID: 32681461
[TBL] [Abstract][Full Text] [Related]
20. An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants.
Shen Y; Ai J; Lin N; Zhang H; Li Y; Wang H; Wang S; Wang Z; Li T; Sun F; Fan Z; Li L; Lu Y; Meng X; Xiao H; Hu H; Ling Y; Li F; Li H; Xi C; Gu L; Zhang W; Fan X
Emerg Microbes Infect; 2022 Dec; 11(1):1518-1523. PubMed ID: 35579892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
